Inclusive of all taxes
Abiraterone Acetate Tablets IP 250mg is a prescription oncology medicine formulated for the treatment of advanced prostate cancer, including metastatic castration-resistant prostate cancer (CRPC) and high-risk castration-sensitive prostate cancer (CSPC). The active ingredient, abiraterone acetate, works by inhibiting androgen biosynthesis and reducing testosterone production, helping to slow the progression of prostate cancer. This 250mg tablet is typically prescribed as part of a combination regimen with prednisone or prednisolone to help reduce treatment-related side effects. For best absorption and therapeutic effect, the tablet must be taken on an empty stomach—no food for 2 hours before or 1 hour after the dose. The tablet should be swallowed whole with water and not crushed or chewed. Abiraterone acetate tablets are widely used in specialist cancer care settings where controlled dosing, routine monitoring, and long-term treatment compliance are essential. Ongoing medical supervision is important because the medicine may cause fluid retention, hypertension, low potassium levels, diarrhea, and elevated liver enzymes. Patients generally require periodic monitoring of liver function tests (LFTs), blood pressure, and serum potassium during therapy. For B2B buyers such as hospitals, oncology clinics, cancer treatment centers, and licensed pharmaceutical distributors, Abiraterone Acetate Tablets IP 250mg is a high-demand oncology formulation used in prostate cancer treatment protocols. The bottle packing format supports convenient dispensing and inventory management in clinical and wholesale supply chains.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Abiraterone Acetate |
| Strength | 250mg |
| Dosage Form | Tablets |
| Therapeutic Use | Prostate cancer treatment |
| Administration Requirement | Must be taken on an empty stomach |
| Packing Type | Bottle |
| Attributes | Description |
|---|---|
| Product Title | ABIRATERONE ACETATE TABLETS IP 250MG |
| Brand/Store Name | RADHAKRUSHNA MEDICALS |
| MOQ | 1 |
| DOM Unit | Bottle |
| Medicine Type | Prescription oncology medicine |
| Salt Name | Abiraterone Acetate |
| Strength | 250mg |
| Dosage Form | Tablet |
| Therapeutic Segment | Oncology |
| Primary Indication | Metastatic castration-resistant prostate cancer (CRPC), high-risk castration-sensitive prostate cancer (CSPC) |
| Administration | Oral |
| Food Instruction | Take on an empty stomach; no food 2 hours before and 1 hour after dosing |
| Co-therapy | Usually used with prednisone or prednisolone |
| Tablet Handling | Swallow whole with water; do not crush or chew |
| Monitoring Requirements | LFT, blood pressure, potassium levels |
| Common Side Effects | Fluid retention, hypertension, diarrhea, hypokalemia, elevated liver enzymes |
| Storage | Store as per pharmacy/manufacturer instructions |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Food can significantly affect the absorption of abiraterone, so it must be taken on an empty stomach for consistent therapeutic levels. The tablet should be taken at least 2 hours after food and no food should be eaten for 1 hour after the dose.
Prednisone or prednisolone is commonly co-prescribed to help manage abiraterone-related mineralocorticoid side effects such as fluid retention, hypertension, and low potassium levels.
Regular monitoring of liver function tests, blood pressure, and serum potassium is important because the medicine may cause elevated liver enzymes, hypertension, and hypokalemia.
No. Abiraterone Acetate Tablets should be swallowed whole with water and must not be crushed or chewed.
It is indicated for metastatic castration-resistant prostate cancer (CRPC) and high-risk castration-sensitive prostate cancer (CSPC).
Inclusive of all taxes
You Save: 0
